

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE FINANCIAL PERIOD ENDED 31 DECEMBER 2023<sup>(1)</sup>

		INDIVIDUAL	QUARTER	CUMULATI	VE PERIOD
		UNAUDITED CURRENT QUARTER ENDED	UNAUDITED COMPARATIVE QUARTER ENDED	UNAUDITED CUMULATIVE PERIOD TO DATE ENDED	UNAUDITED CUMULATIVE PRECEDING PERIOD TO DATE ENDED
	Note	31 DECEMBER 2023 RM'000	31 DECEMBER 2022 RM'000	31 DECEMBER 2023 RM'000	31 DECEMBER 2022 RM'000
Revenue	A9	15,940	-	44,578	-
Cost of sales		(9,370)	-	(28,659)	-
Gross profit		6,570	-	15,919	-
Other income		431	-	1,301	-
Administrative expenses		(3,649)	-	(11,753)	-
Selling and distribution expenses		(487)	-	(1,705)	-
Other expenses		1,840	-	(5,748)	-
Net loss on impairment of financial assets		(278)	-	(325)	-
Share of profit of an associate		-	-	-	-
Profit/(Loss) from operations		4,427		(2,311)	-
Finance costs		(280)	-	(579)	-
Profit/(Loss) before taxation (" <b>PBT</b> " or "LBT")	)	4,147		(2,890)	
Tax expense	B4	(4,092)	-	(4,093)	-
Profit/(Loss) after taxation ("PAT" or "LAT")		55		(6,983)	
Other comprehensive income		-	-	-	-
Total comprehensive income/(expense) for the financial period		55		(6,983)	
Total comprehensive income/(expense) for the financial period attributable to:- Owners of the Company Non-controlling interests		44 55		(6,978) (5) (6,983)	- - -
Earnings/(Loss) per share (sen) - Basic <sup>(2)</sup>	B11	0.01		(2.18)	

Notes:-

(1) The basis of preparation of the Unaudited Condensed Consolidated Statements of Profit or loss and Other Comprehensive Income is detailed in Note A1 and should be read in conjunction with the audited financial statements for the financial period ended ("FPE") 31 December 2022 and the accompanying explanatory notes attached to this interim financial report.

(2) Basic earnings/(loss) per share is calculated based on the weighted average number of ordinary shares in issue.

(3) The financial year end of the Company and the Group has changed from 30 September to 31 December as announced to Bursa Malaysia Securities Berhad on 22 April 2022. The financial statements for the last financial period were prepared for a 15 months period from 1 October 2021 to 31 December 2022. This is the first set of the interim financial statements prepared for the current financial year of 12 months ending 31 December 2023. As such, there are no comparative figures available for the corresponding periods in the preceding financial period.



UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION AS AT 31 DECEMBER 2023 (1)

Να	UNAUDITED AS AT 31 DECEMBER 2023 ote RM'000	AUDITED AS AT 31 DECEMBER 2022 RM'000
ASSETS		
Non-current Assets		
Property, plant and equipment	74,029	63,923
Right-of-use assets	3,832	3,121
Goodwill	-	-
Investment in an associate company	-	-
Investment in quoted shares	38,015	24,704
	115,876	91,748
Current Assets		
Inventories	16,619	10,413
Trade receivables	11,977	7,640
Other receivables, deposits and prepayments	21,883	9,657
Amount owing by a related party	228	228
Current tax assets	(1,138)	4,079
Fixed deposit with licensed bank	20,380	12,000
Cash and bank balances	16,190	14,708
	86,141	58,725
Assets included in disposal group classified as held for sale	11,811	_
Assets included in disposal group classified as field for sale	97,952	
TOTAL ASSETS	213,828	150,473
EQUITY AND LIABILITIES		
Equity		
Share capital	240,262	191,704
Merger deficit	(29,580)	(29,580)
Accumulated losses	(39,021)	(32,048)
Equity attributable to owners of the Company	171,661	130,076
Non-controlling interests	(638)	(668)
TOTAL EQUITY	171,023	129,408
Non-current Liabilities Lease liabilities B	8 2,050	1,214
	8 2,050 8 6,616	6,734
Bank bonowings	8,666	7,948
Current Liabilities		
Trade payables	338	1,668
Other payables and accruals	10,461	8,420
-	8 22,131	1,828
Lease liabilities B	8 1,208	1,201
	34,138	13,117
TOTAL LIABILITIES	42,805	21,065
TOTAL EQUITY AND LIABILITIES	213,828	150,473
Net asset per share (RM) <sup>(2)</sup>	0.44	1.34

#### Notes:-

- (1) The basis of preparation of the Unaudited Condensed Consolidated Statements of Financial Position is detailed in Note A1 and should be read in conjunction with the audited financial statements for the FPE 31 December 2022 and the accompanying explanatory notes attached to this interim financial report.
- (2) Net asset per share is calculated based on the number of ordinary shares in issue of 388,057,256 shares as at 31 December 2023 and 97,160,054 shares as at 31 December 2022.



UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY FOR THE FINANCIAL PERIOD ENDED 31 DECEMBER 2023 (1)

	< Non-Distril	Attributable to Equity outable>	Holders of the Company	>		
	Share Capital	Merger Deficit	Accumulated Losses	Total Attributable to Owners of Company	Non-controlling Interests	Total Equity
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
Balance at 1 January 2023	191,704	(29,580)	(32,048)	130,076	(668)	129,408
Transactions with owners Ordinary shares issued pursuant to:						
- Right issue with warrants	49,452	-	-	49,452	-	49,452
- Share issuance expenses	(894)	-	-	(894)	-	(894)
	48,558	-	-	48,558	-	48,558
Disposal of shares to non-controlling interest	-	-	5	5	35	40
Loss and other comprehensive expense for the financial period	-	-	(6,978)	(6,978)	(5)	(6,983)
Balance at 31 December 2023	240,262	(29,580)	(39,021)	171,661	(638)	171,023

Note:-

- (1) The basis of preparation of the Unaudited Condensed Consolidated Statements of Financial Position is detailed in Note A1 and should be read in conjunction with the audited financial statements for the FPE 31 December 2022 and the accompanying explanatory notes attached to this interim financial report.
- (2) The financial year end of the Company and the Group has changed from 30 September to 31 December as announced to Bursa Malaysia Securities Berhad on 22 April 2022. The financial statements for the last financial period were prepared for a 15 months period from 1 October 2021 to 31 December 2022. This is the first set of the interim financial statements prepared for the current financial year of 12 months ending 31 December 2023. As such, there are no comparative figures available for the corresponding periods in the preceding financial period.



UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE FINANCIAL PERIOD ENDED 31 DECEMBER 2023 (1)

	PERIOD ENDED 31 DECEMBER 2023	PERIOD ENDED 31 DECEMBER 2022
	ST DECEMBER 2025 RM'000	RM'000
CASH FLOWS FROM OPERATING ACTIVITIES		
Loss before taxation	(2,890)	-
Adjustments for:		
Depreciation of property, plant and equipment	4,066	-
Gain on disposal of property, plant and equipment	(15)	-
Depreciation of right-of-use assets	1,415	-
Interest expense	733	-
Interest income	(659)	-
Impairment losses on property, plant and equipment	29	
Net reversal of written down on inventories	630	-
Net impairment loss on trade receivables	325	-
Net impairment gain on non-trade receivables	(6,038)	
Fair value loss on investment in quoted shares	2,464	-
Fair value gain on investment in other investment	(158)	
Unrealised gain on foreign exchange	(78)	
Operating profit before working capital changes	(176)	-
Increase in inventories	(6,836)	-
Increase in trade and other receivables	(10,932)	-
Decrease in trade and other payables	711	-
CASH USED IN OPERATIONS	(17,233)	-
	(242)	
Income tax paid	(343)	-
Income tax refunded	1,468 659	-
Interest received	(15,449)	
	(10) 10)	
CASH FLOWS FROM INVESTING ACTIVITIES		
Acquisition of property, plant and equipment	(37,808)	-
Acquisition of investment in quoted shares	(4,412)	-
Acquisition of investment in other investments	158	
Acquisition of right-of-use asset	(517)	-
Increase in pledged fixed deposit with a licensed bank	(20,380)	-
Proceeds from disposal of quoted shares	(11,363)	
Proceeds from disposal of property, plant and equipment	11,810	-
Proceeds from disposal of investment in subsidiaries	40	-
Termination adjustment of right-of-use asset	328	
NET CASH USED IN INVESTING ACTIVITIES	(62,144)	<u> </u>
CASH FLOWS FROM FINANCING ACTIVITIES		
Drawdown of bankers' acceptances	2,061	-
Net proceeds from issuance of ordinary shares via right issue with warrants	48,558	-
Repayment of hire purchase	(8)	
Repayment of lease liabilities	(1,086)	-
Repayment of term loans	(1,955)	-
Interest paid	(526)	
NET CASH GENERATED FROM FINANCING ACTIVITIES	47,044	-
NET DECREASE IN CASH AND CASH EQUIVALENTS	(30,550)	-
EFFECTS OF FOREIGN EXCHANGE RATE CHANGES ON THE	(30,330)	
BALANCE	159	-
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE FINANCIAL PERIOD	26,708	-
CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL PERIOD	(3,683)	-
·		



UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE FINANCIAL PERIOD ENDED 31 DECEMBER 2023 (1)

	UNAUDITED PERIOD ENDED 31 DECEMBER 2023 RM'000	UNAUDITED PERIOD ENDED 31 DECEMBER 2022 RM'000
Cash and cash equivalents at end of the financial period comprise the following	ng:	
Cash and bank balances	16,190	-
Fixed deposit with a licensed bank	20,380	-
Bank overdraft	(19,873)	-
	16,698	-
Less: Fixed deposit pledged with a licensed bank	(20,380)	-
	(3,683)	-

#### Note:-

- (1) The basis of preparation of the Unaudited Condensed Consolidated Statements of Cash Flows is detailed in Note A1 and should be read in conjunction with the audited financial statements for the FPE 31 December 2022 and the accompanying explanatory notes attached to this
- (2) The financial year end of the Company and the Group has changed from 30 September to 31 December as announced to Bursa Malaysia Securities Berhad on 22 April 2022. The financial statements for the last financial period were prepared for a 15 months period from 1 October 2021 to 31 December 2022. This is the first set of the interim financial statements prepared for the current financial year of 12 months ending 31 December 2023. As such, there are no comparative figures available for the corresponding periods in the preceding



# A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS ("MFRS") 134: INTERIM FINANCIAL REPORTING

# A1. Basis of preparation

The interim financial report of LKL International Berhad ("**LKL International**" or "**the Company**") and its subsidiaries ("**the Group**") is unaudited and has been prepared in accordance with the requirements of MFRS 134 - Interim Financial Reporting issued by the Malaysian Accounting Standard Board ("**MASB**"), Paragraph 9.22 and Appendix 9B of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad ("**Bursa Securities**").

The interim financial report should be read in conjunction with the audited financial statements for the financial period ended 31 December 2022 ("FPE 2022"). These explanatory notes attached to the interim financial report provide explanation of events and transactions that are significant for the understanding of the changes in the financial position and performance of the Group since the FPE 2022.

# A2. Changes in accounting policies

The significant accounting policies adopted by the Group in this interim financial report are consistent with those adopted in the audited financial statements of the Group for the financial period ended 31 December 2022 except for the adoption of the following new accounting standards, amendments and interpretation:

		Effective Date
Amendments to MFRS 17:	Insurance Contracts	1 January 2023
Amendment to MFRS 17:	Initial Applications of MFRS 9 and MFRS 17 Comparative Information	1 January 2023
Amendments to MFRS 101 and		
MFRS Practice Statement 2:	Disclosures of Accounting Policies	1 January 2023
Amendments to MFRS 108:	Definition of Accounting Estimates	1 January 2023
Amendments to MFRS 112:	Deferred Tax Related to Assets and Liabilities Arising from a Single	
	Transaction and International Tax Reform - Pillar Two Model Rules	1 January 2023

The adoption of the above amendments to MFRSs does not have a material impact on the financial statements of the Group.

The Group has not applied in advance the following accounting standards and/or interpretations (including the consequential amendments, if any) that have been issued by the MASB but are not yet effective for this interim financial report: -

		Effective Date
Amendments to MFRS 7 and		
MFRS 107:	Supplier Financial Arrangements	1 January 2024
Amendments to MFRS 16:	Lease Liability in a Sale and Leaseback	1 January 2024
Amendments to MFRS 101:	Classification of Liabilities as Current or Non-current and Non-current Liabilities with Covenants	1 January 2024
Amendments to MFRS 121: Amendments to MFRS 10 and	Lack on Exchangeability	1 January 2024
MFRS 128:	Sales or Contribution of Assets between an Investor and its Associate or Joint Venture	Deferred until further notice

The adoption of the above accounting standards and/or interpretations (including the consequential amendments, if any) is expected to have no material impact on the interim financial report of the Group upon its initial application.



# NOTES TO THE INTERIM FINANCIAL REPORT FOR THE FINANCIAL PERIOD ENDED 31 DECEMBER 2023

# A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS ("MFRS") 134: INTERIM FINANCIAL REPORTING (CONT'D)

#### A3. Auditors' report on preceding audited financial statements

The preceding year's audited financial statements of the Group were not subject to any qualification.

#### A4. Seasonal or cyclical factors

The Group's business operations were not materially affected by seasonal or cyclical factors during the current financial quarter under review.

#### A5. Unusual items affecting assets, liabilities, equity, net income or cash flows

There were no material unusual items affecting assets, liabilities, equity, net income or cash flows of the Group during the current financial quarter and current period-to-date under review except as disclosed in the unaudited financial statements.

#### A6. Material changes in estimates

There were no changes in estimates that have had a material effect in the current financial quarter under review.

#### A7. Debts and equity securities

There was no other issuance, cancellation, repurchase, resale and repayment of debt and equity securities during the current financial quarter under review.

#### A8. Dividend paid

There was no dividend paid during the current financial quarter under review.

#### A9. Segmental information

#### (a) Analysis of revenue by product categories

		UNAU	DITED			UNAU	DITED	
	11	NDIVIDUA	L QUARTER		C	UMULATI	VE PERIOD	
	31 DECE	MBER	31 DECEM	IBER	31 DECE	MBER	31 DECEM	BER
	202	23	2022		202	23	2022	
	RM'000	%	RM'000	%	RM'000	%	RM'000	%
Manufacturing:								
Medical/healthcare								
beds	2,895	18.16	-	-	9,390	21.06	-	-
Medical peripherals								
and accessories	5,148	32.30	-	-	20,207	45.33	-	-
	8,043	50.46	-	-	29,597	66.39	-	-
Trading:							-	-
Medical peripherals								
and accessories	7,292	45.74	-	-	13,953	31.30	-	-
Medical devices	32	0.20	-	-	61	0.14	-	-
	7,324	45.94	-	-	14,014	31.44	-	-
Retail:								
Healthcare and								
Pharmaceuticals	573	3.6	-	-	967	2.17	-	-
Total revenue	15,940	100.00	-	-	44,578	100.00	-	-



# A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS ("MFRS") 134: INTERIM FINANCIAL REPORTING (CONT'D)

# A9. Segmental information (Cont'd)

(b) Analysis of revenue by geographical areas

	۱۱ 31 DECE 202	MBER	DITED L QUARTER 31 DECEM 2022	BER	C 31 DECE 202	MBER	DITED VE PERIOD 31 DECEM 2022	BER
	RM'000	%	RM'000	%	RM'000	%	RM'000	%
Local:								
Malaysia	15,260	95.74	-	-	40,195	90.17	-	-
<b>Export:</b> Africa Asia - other than	233	1.46	-	-	1,553	3.48	-	-
Malaysia	447	2.80	-	-	2,575	5.78	-	-
Europe		-	-	-	55	0.12	-	-
Middle East		-	-	-	200	0.45	-	-
	680	4.26	-	-	4,383	9.83	-	-
Total revenue	15,940	100.00	-	-	44,578	100.00	-	-

# A10. Valuation of property, plant and equipment

There was no valuation of the property, plant and equipment for the current financial quarter under review.

# A11. Material events subsequent to the end of the current financial quarter

There were no other material events subsequent to the end of the current financial quarter that have not been reflected in this interim financial report.

#### A12. Changes in composition of the Group

There were no material changes in the composition of the Group for the current financial quarter under review.

#### A13. Contingent assets or contingent liabilities

The Group has no other contingent assets and contingent liabilities as at the date of this report except for the following:

a) Contingent liabilities

	UNAUDITED AS AT	AUDITED AS AT 31 DECEMBER
	31 DECEMBER 2023 RM'000	2022 RM'000
Bank guarantees given by financial institution to third parties	786	606



NOTES TO THE INTERIM FINANCIAL REPORT FOR THE FINANCIAL PERIOD ENDED 31 DECEMBER 2023

A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS ("MFRS") 134: INTERIM FINANCIAL REPORTING (CONT'D)

#### A14. Capital commitments

	UNAUDITED AS AT 31 DECEMBER	AUDITED AS AT 31 DECEMBER
	2023 RM'000	2022 RM'000
Approved and contracted for: Purchase of property, plant and equipment	39,599	2,077

# A15. Related party transactions

Significant related party transactions for the financial period to date are as follows :

RM'000

Transactions with a company in which the major shareholder of the Company, Bioalpha Holding Berhad has substantial interests:

Mediconstant Pharmacy Sdn. Bhd.

- Outlets management fee p	aid	180
- Promotion and marketing f	ee paid	30
<ul> <li>Manpower related paid</li> </ul>		239
- Shoplot sublease rent & uti	ilities related paid	378
- Purchase of pharmaceutica	Il products, medical,	
healthcare equipment and	pharmacy related.	7,122

Transactions with a company in which a director of the Company, Datuk Chong Loong Men has substantial interests: Parlo Tours Sdn. Bhd.

 Purchase of travel services including airline ticket and hotel bookings

310



# B. ADDITIONAL INFORMATION REQUIRED BY THE LISTING REQUIREMENTS OF BURSA SECURITIES

# B1. Review of performance of 12-month ended 31 December 2023 ("4Q 2023")

The financial year end of the Company and the Group has changed from 30 September to 31 December as announced to Bursa Malaysia Securities Berhad on 22 April 2022. The financial statements for the last financial period were prepared for a 15 months period from 1 October 2021 to 31 December 2022. This is the first set of the interim financial statements prepared for the current financial year of 12 months ending 31 December 2023. As such, there are no comparative figures available for the corresponding periods in the preceding financial period.

The Group's performance for the 4Q 2023 is as tabled below:

	UNAUDITED 4Q 2023 RM'000
Revenue	44,578
Gross profit Loss Before Tax	15,919
("LBT")	(2,890)

The Group posted revenue of RM44.578 million on the back of continuous orders of key products including medical/ healthcare beds, and medical peripherals and accessories delivered from the manufacturing segment for the current financial period. Geographically, the domestic front remains as the main contributor at RM40.195 million or 90.17% of the group revenue whereby the remaining revenue of RM4.383 million or 9.83% of the group revenue was generated from exports, mainly to the Asia and Africa regions for the current financial period.

The Group reported a gross profit of RM15.919 million and gross profit margin of 35.71% for the current financial period despite a gross loss incurred during the first five months of the operations of the six new pharmacy outlets which have commenced businesses in August 2023.

The Group posted a LBT of RM2.890 million for the current financial period mainly due to an impairment made in relation to the glove inventories and initial set up cost and operating loss incurred from pharmacy business during the current financial period.

# Manufacturing Segment

The manufacturing segment of medical/ healthcare beds, medical peripherals and accessories delivered orders totaling RM29.597 million or 66.39% of the group revenue for the current financial period mainly to the orders received from the government and private healthcare centers.



# B. ADDITIONAL INFORMATION REQUIRED BY THE LISTING REQUIREMENTS OF BURSA SECURITIES (CONT'D)

# B1. Review of performance of 12-month ended 31 December 2023 ("4Q 2023") (Cont'd)

#### **Trading Segment**

The trading segment of medical peripherals, accessories and medical devices contributed RM9.035 million or 20.27% of group revenue and the sales of medical gloves contributed RM4.979 million or 11.17% for the current financial period.

This segment posted a gross loss of RM2.608 million and a gross loss margin of -18.91% mainly due to impairments made to the medical gloves inventories for the current financial period.

Consequently, this segment posted an operating loss of RM1.148 million from the operations before interest and tax expense for the current financial period mainly due the reasons as stated above.

#### **Pharmacy Retail Segment**

The revenue contributed from the pharmacy retail segment improved to RM0.967 million for the current financial period following the opening of six new pharmacy outlets located in the major cities in Klang Valley in August 2023, represent 2.17% of the group revenue for the current financial period.

Due to the higher outlet initial set up cost and lower sales volume resulting from poor pricing power, this segment registered a gross loss of RM1.343 million for the current financial period, and consequently, this segment posted an operating loss of RM2.046 million before interest and tax mainly due to reasons stated above.

#### Investment Holding Segment

This segment continues to register an loss of RM3.261 million for the current financial period due to the loss on the fair value of quoted investments of RM2.464 million.

#### B2. Comparison with preceding quarter's results

	UNAUDITED CURRENT QUARTER ENDED 31 DECEMBER 2023 RM'000	UNAUDITED PRECEDING QUARTER ENDED 30 SEPTEMBER 2023 RM'000
Revenue	15,940	8,821
Gross profit	532	2,026
Profit Before Tax ("PBT")	4,147	1,045

The Group recorded a higher revenue of RM15.940 million for the current financial quarter as against RM8.821 million in the preceding financial quarter, mainly due to several large projects delivered during the current quarter.



# B. ADDITIONAL INFORMATION REQUIRED BY THE LISTING REQUIREMENTS OF BURSA SECURITIES (CONT'D)

### B2. Comparison with preceding quarter's results (Cont'd)

The Group had registered an improved PBT of RM4.147 million in the current financial quarter as compared to RM1.045 million in the preceding financial quarter, mainly due to higher revenue recorded in the current quarter.

#### B3. Prospects

The COVID-19 pandemic restricted economic activities and impacted sectoral production adversely through both supply and demand shocks. As these shocks fades and the economy gradually recover, the Group seeks to seize this opportunity to venture into several approved expansions requiring a more significant utilising area and bigger space of its existing facilities to streamline the production flow effectively and for additional warehousing to cope with existing and additional production capacity.

Since the Company listed in 2016, it is part of the long-term strategy plans of LKL to expand its existing production capacity to cope with growing demands and going global. The existing facilities are nearing full capacity as our existing production team, and warehouse have not grown for the past few years while our business is overgrowing. The approved expansions of the Group are to better navigate LKL to the evolution of the latest global healthcare transformation for a more prominent market share in the healthcare industries.

Furthermore, the Board anticipates the growing business in East Malaysia and has thus established its subsidiary in Sarawak. The Group believes that setting up LKL Medical Sarawak Sdn Bhd would be beneficial in accommodating market demands in East Malaysia and will help yield higher profits for the business.

COVID-19 brought seismic shifts to everyday life for each of us and how we operate as a global society. Higher vigilant, along with raised awareness was placed on the importance of the healthcare sector. Post covid symptoms and long-term effects concern the general public and people are seeking ways to keep oneself healthier, for example through better hygiene keeping, intake of supplements, regular and more frequent medical checkups. Demands for all varieties of remote healthcare spiked and pharmacies stepped up and effectively providing all sorts of healthcare services for the general public.

To tap into these opportunities, the Group has a total of seven pharmacy outlets including six new pharmacy outlets, namely Constant Pharmacy to serve the community of the major areas in Klang Valley. This expansion plan will improve our pricing power immediately as a result of more volumes generated from more outlets. The Board will continue to set up more strategic outlets to enjoy prominent savings in the supply chain in return more savings for customers.

With the upward trend of US dollar and our Ringgit suffering comes a hike of price of raw materials. In order to navigate this, our manufacturing unit continues in leveraging on its strong fundamentals in technology competency, quality assurance, customer satisfaction and long-term relationship, and focus on improving its business strategy by streamlining its operations, expanding its high profitable product range, enhancing infrastructures and accelerating process automations to shorten the delivery lead times and reduce production wastage, are essential to improve the profitability of the Group.

The Government's allocation of RM41.22 billion for the Ministry of Health (MOH) in Budget 2024 reflects a higher attention on the Healthcare sector. With that, the Group maintains optimistic outlook on its future and intents to promote the importance of healthcare sector at its highest potential.



# B. ADDITIONAL INFORMATION REQUIRED BY THE LISTING REQUIREMENTS OF BURSA SECURITIES (CONT'D)

#### B4. Tax expense

	UNAUDITED INDIVIDUAL QUARTER ENDED 31 DECEMBER 2023 RM'000	UNAUDITED CUMULATIVE PERIOD ENDED 31 DECEMBER 2023 RM'000
Current tax expense	2,775	2,775
Under provision in prior financial period	1,318	1,318
	4,093	4,093

#### B5. Variance of actual profit from profit forecast and profit guarantee

The Group has not issued any profit forecast or profit guarantee in any form of public documentation and announcement during the current financial quarter under review.

#### B6. Status of corporate proposals

There were no corporate proposals announced but not completed as at the date of this report.

# **B7.** Utilisations of proceeds from corporate exercises

a) Pursuant to the Right Issue with Warrants, the details of the issuance of Right Shares as at the date of this report are as follows:

Issuance Date	No. of Shares	Issue Price (RM)	Total Proceeds (RM)
28 March 2023	290,897,202	0.17	49,452,524

The status of utilisation of proceeds as at the date of this report is as follows:

	Purposes	Proceeds raised RM'000	Actual utilisation RM'000	Deviation RM'000	Unutilised proceeds RM'000	Estimated timeframe for utilisation
(a)	Expansion of the pharmacy business	48,353	13,116	206	35,442	Within 24 months
(b)	Estimated expenses in relation to the Proposals	1,100	894	(206)	-	Immediate
	Total	49,453	14,010	-	35,442	

#### Note:-

(1) In view that the actual listing expenses were less than estimated, the surplus has been re-allocated for expansion of the pharmacy business.



# B. ADDITIONAL INFORMATION REQUIRED BY THE LISTING REQUIREMENTS OF BURSA SECURITIES (CONT'D)

### B8. Group's borrowings and debt securities

The Group's borrowings as at 31 December 2023 were as follows:

	UNAUDITED AS AT 31 DECEMBER 2023 RM'000	AUDITED AS AT 31 DECEMBER 2022 RM'000
Current:		
Bank overdraft	19,873	-
Bankers' acceptance	2,061	1,426
Lease liabilities	1,208	1,201
Term loans	197	402
	23,339	3,029
Non-current:		
Lease liabilities	2,050	1,214
Term loans	6,616	6,734
	8,666	7,948
Total borrowings:		
Bank overdraft	19,873	-
Bankers' acceptance	2,061	1,426
Lease liabilities	3,258	2,415
Term loans	6,813	7,136
	32,005	10,977

All the borrowings were secured and denominated in Ringgit Malaysia.

#### **B9.** Material litigation

Save as disclosed below, there is no litigation or arbitration which has a material effect on the financial position of the Group and the Board of Directors is not aware of any proceedings pending or threatened, or of any fact likely to give rise to any proceedings as at the date of this report.

# (i) LKL Advance Metaltech Sdn. Bhd. vs Crecom Burj Gloves Sdn. Bhd. (WA-24NCC(ARB)-37-12/2020)

On 16 December 2020, LKL Advance Metaltech Sdn. Bhd. ("LKLAM") had through its solicitors, Messrs. Chong + Kheng Hoe, filed an Originating Summons in the High Court in Kuala Lumpur bearing registration number: WA24NCC(ARB)-37-12/2020 ("OS") against Crecom Burj Gloves Sdn. Bhd. ("Defendant").

The High Court had on 5 March 2021 granted a Mareva injunction to freeze the Defendant's asset up to the amount of RM12,542,784 after hearing all parties involved.

The Defendant has been wound up on 29 September 2022. The Defendant's liquidator had on 20 September 2023 filed an application to set aside the Mareva injunction. Parties had on 6 November 2023 recorded a consent order to set aside the Mareva injunction on the condition that, amongst others, the Defendant's liquidator accept and admit the Plaintiff's Proof of Debt lodged with the Defendant's liquidator.



# B. ADDITIONAL INFORMATION REQUIRED BY THE LISTING REQUIREMENTS OF BURSA SECURITIES (CONT'D)

### B9. Material litigation (Cont'd)

Save as disclosed below, there is no litigation or arbitration which has a material effect on the financial position of the Group and the Board of Directors is not aware of any proceedings pending or threatened, or of any fact likely to give rise to any proceedings as at the date of this report. (Cont'd)

## (i) LKL Advance Metaltech Sdn. Bhd. vs Crecom Burj Gloves Sdn. Bhd. (WA-24NCC(ARB)-37-12/2020) (Cont'd)

In line with the OS, LKLAM had also filed a Notice of Arbitration dated 11 January 2021 ("Arbitration") against the Defendant. LKLAM claims against the Defendant for breach of the Purchase Agreement dated 2 October 2020 which was entered into by both parties for the purchase of gloves from the Defendant. In the Arbitration, LKLAM is seeking from the Defendant the sum of RM12,542,784, general damages, interest, costs and any further relief that the arbitral tribunal thinks fit and just.

The Defendant filed a Response to the Arbitration dated 16 February 2021 counterclaiming for the sum of RM20,374,500 for the purported balance amount due to the Defendant. The Arbitration is pending appointment of arbitrator by the director of Asian International Arbitration Centre. There was no progress in the case as at the date of this report.

#### (ii) LKL Advance Metaltech Sdn. Bhd. vs Crecom Burj Gloves Sdn. Bhd. and 6 others (WA-22NCC-331-07/2021)

On 26 July 2021, LKLAM had through its solicitors, Messrs Chong + Kheng Hoe, filed a Writ and Statement of Claim in the High Court in Kuala Lumpur bearing suit number: WA-22NCC-331-07/2021 ("Suit") against Crecom Burj Gloves Sdn. Bhd., Crecom Burj Group Sdn. Bhd., Datin Roslinda Binti Jaafar, Khairil Anuar Bin A. Rahman, Nurul Ashikin Binti Muhammad Muhiyuddin, Chew Seng Ker and Nurul Balqis Binti Khairul Anuar ("Defendant").

LKLAM is claiming against Defendants for the return of RM12,540,757 being payment made by LKLAM for the purchase of gloves from Crecom Burj Group Sdn. Bhd. pursuant to the purchase agreement dated 2 October 2020.

On 23 August 2022, the second Defendant, Crecom Burj Group Sdn. Bhd. has been wound up by the Kuala Lumpur High Court. LKLAM has filed a post-winding up suit no. WA-28PW-620-12/2022 to obtain leave from the Kuala Lumpur High Court to continue the proceeding against the second Defendant, Crecom Burj Group Sdn. Bhd. in suit WA-22NCC-331-07/2021.

On 29 September 2022, the first Defendant, Crecom Burj Gloves Sdn. Bhd. has been wound up by the Shah Alam High Court. LKLAM has filed a post-winding up suit no. BA-28PW-314-12/2022 to obtain leave from the Shah Alam High Court to continue the proceeding against the first Defendant, Crecom Burj Gloves Sdn. Bhd. in suit WA-22NCC-331-07/2021.

Pending the leave hearing and also pending appointment of solicitors for Crecom Burj Group Sdn. Bhd. And Crecome Burj Gloves Sdn. Bhd., the new trial dates are fixed on 20 to 24 May 2024.

# (iii) LKL Advance Metaltech Sdn. Bhd. vs Genesis Gateway Sdn. Bhd. (WA-28NCC-800-11/2021)

On 8 November 2021, LKLAM ("Petitioner") has had through its solicitors, Messrs. Chong + Kheng Hoe, presented a Winding Up Petition at the Kuala Lumpur High Court registered under Companies (Winding-Up) No. WA-28NCC-800-11/2021 against Genesis Gateway Sdn Bhd ("Respondent") for the sum of RM13,311,960.96, indebted by the Respondent to the Petitioner wherein the Petitioner is seeking inter alia for the Respondent to be wound up by the Court and the incidental reliefs related thereto. The Court has also appointed a liquidator of the Respondent and Petitioner has filed their proof of debt to the liquidator on 31 October 2022.



# B. ADDITIONAL INFORMATION REQUIRED BY THE LISTING REQUIREMENTS OF BURSA SECURITIES (CONT'D)

### B9. Material litigation (Cont'd)

Save as disclosed below, there is no litigation or arbitration which has a material effect on the financial position of the Group and the Board of Directors is not aware of any proceedings pending or threatened, or of any fact likely to give rise to any proceedings as at the date of this report (Cont'd)

#### (iv) LKL International Berhad vs The Edge Communications Sdn. Bhd. (WA-23NCvC-50-05/2021)

On 25 May 2021, the Company had through its solicitors, Messrs. Wong Kian Kheong, filed a Writ and Statement of Claim in the High Court in Kuala Lumpur against The Edge Communications Sdn. Bhd. ("The Edge"). The suit was initiated against The Edge for the article published at pages 62 to 64 of "The Edge Malaysia" on 12 April 2021 entitled "Hidden hands behind penny stock surge under scrutiny" ("Article"), of which the Company alleged that certain words in the Article were defamatory of LKL International Berhad.

The Company is seeking from The Edge, amongst others, damages and an injunction to restrain The Edge whether by itself, its agents or servants or otherwise from publishing or causing to be published the same or similar words defamatory of the LKL International.

On 19 August 2021, the Edge filed a striking out application to strike out the Company's claim, and the High Court has on 17 May 2022 dismissed The Edge's striking application with costs in the cause. The Court has vacated the trail scheduled on 15 to 17 January 2024. New trial dates will be fixed.

#### B10. Dividend proposed

There was no dividend proposed for the current financial quarter under review.

# B11. Earnings/(Loss) per share ("EPS" or "LPS")

The basic EPS or LPS for the current financial quarter and financial period-to-date are computed as follows:

	UNAUDITED INDIVIDUAL QUARTER ENDED 31 DECEMBER 2023	UNAUDITED CUMULATIVE PERIOD ENDED 31 DECEMBER 2023
Net profit/(loss) attributable to ordinary equity holders of the Company (RM'000)	44	(6,978)
Weighted average number of ordinary shares in issue ('000)	388,057	319,517
Basic EPS/LPS (Sen)	0.01	(2.18)



# B. ADDITIONAL INFORMATION REQUIRED BY THE LISTING REQUIREMENTS OF BURSA SECURITIES (CONT'D)

# B12. Notes to the Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Income

PBT or LBT is arrived at after charging/(crediting):

	UNAUE INDIVIDUAL QU	ARTER ENDED	UNAUDITED CUMULATIVE PERIOD ENDED		
	31 DECEMBER 2023 RM'000	31 DECEMBER 2022 RM'000	31 DECEMBER 2023 RM'000	31 DECEMBER 2022 RM'000	
Depreciation of property, plant and					
equipment	2,519	-	4,066	-	
Gain on disposal of property, plant and					
equipment	-	-	(15)	-	
Depreciation of right-of-use assets	420	-	1,415	-	
Interest expense	322	-	733	-	
Interest income	(170)	-	(659)	-	
Net reversal of written down on inventories	738	-	630	-	
Impairment loss on trade receivables	278	-	325	-	
Fair value (gain)/loss on investment					
in quoted shares	(3,644)	-	2,464	-	
Unrealised Gain on foreign exchange	(32)		(78)	-	

Other disclosure items pursuant to Appendix 9B Note 16 of the ACE Market Listing Requirements of Bursa Securities are not applicable.

# B13. Authorisation for Issue

The interim financial report was authorised for issue by the Board of Directors on 29 February 2024.